Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
After failing to bounce reinstatement claims by women alleging sex discrimination, Goldman Sachs has asked the 2nd U.S. Circuit Court of Appeals to step in. On Monday, the bank’s lawyers at Sullivan & Cromwell filed a request for interlocutory appeal, arguing that the 2nd Circuit should consider two novel questions stirred up in a long-running class action by women who claim they were underpaid, unfairly evaluated and ultimately lost or left their jobs because Goldman treated women differently than men.
For a moment during U.S. Supreme Court oral arguments last April in California Employees’ Retirement System v. ANZ Securities, it looked as though something remarkable was happening: Chief Justice John Roberts seemed to be on the verge of siding with plaintiffs in a case heavily lobbied by business groups.
The U.S. House Judiciary Committee is intensifying its scrutiny of advertising by personal injury lawyers looking for clients injured by pharmaceuticals. On Friday, the committee will hear about the consequences of legal advertising from four witnesses – two doctors who say in written statements that they’ve seen patients die because lawyers’ ads scared them off of their medications; a legal ethics expert who argues there’s no need for additional regulation of legal advertising; and a scholar of legal advertising who said in a fascinating and fact-packed overview that no widescale study has established a link between lawyers’ ads and patient decisions.
If you want to know just how ugly litigation can get, check out the Manhattan federal court docket in Tantaros v. Fox News.
A data-crunching startup called hiQ relies entirely on the public profiles of LinkedIn users. HiQ sells “people analytics” to companies including eBay, Capital One and GoDaddy, scrutinizing employees’ LinkedIn profiles to advise clients on managing their workforces. HiQ employs 24 people and has raised $14.5 million in venture capital on the premise of access to information that LinkedIn users have agreed to allow the world to see.
The Trump administration, as Reuters was the first to report on Friday, has ditched the National Labor Relations Board in one of the biggest business cases the U.S. Supreme Court will hear in its next term. Instead of backing the NRLB, which asserts that the National Labor Relations Act bars employers from forcing employees to give up their right to bring classwide actions, the solicitor general’s office filed an amicus brief supporting Ernst & Young, Epic Systems and Murphy Oil, all of which require employees to arbitrate disputes individually.
I’ve been touting Conagra Brands’ petition asking the U.S. Supreme Court to take up the red-hot issue of class action ascertainability as an early test of the class action appetite of the newly constituted court. But in an opposition brief filed Friday, members of the class suing Conagra over its “all-natural” labels contend the Supreme Court has already addressed the only real issue Conagra’s petition raises, in 2016’s Tyson Foods v. Bouaphakeo.
Is the U.S. attorney’s office in Manhattan manipulating the indictment process to get insider-trading cases before judges it considers friendly?
In more than two hours of testimony before the U.S. Senate Intelligence Committee on Tuesday afternoon, Attorney General Jeff Sessions had some harsh words for fired FBI director James Comey. But if special counsel Robert Mueller is looking for near-contemporaneous corroboration of Comey's state of mind after a critical and disputed conversation with President Trump, Sessions provided it.
It’s always revealing to track amicus filings by groups like the U.S. Chamber of Commerce, the National Association of Manufacturers and the Washington Legal Foundation. I regard amicus briefs from the business lobby as a rough index of litigation threats to U.S. companies - or, at least, an indicator of what companies perceive to be litigation threats. Based on that assumption, it looks like businesses, and, in particular, pharmaceutical companies, are still worried about the prospect of treble damages in racketeering suits by alleged victims at the end of supposedly fraudulent schemes.